{"id":1194,"date":"2026-09-03T09:32:25","date_gmt":"2026-09-03T13:32:25","guid":{"rendered":"https:\/\/aramisbiotechnologies.com\/a-propos\/nouvelles\/"},"modified":"2026-10-13T16:04:17","modified_gmt":"2026-10-13T20:04:17","slug":"nouvelles","status":"publish","type":"page","link":"https:\/\/aramisbiotechnologies.com\/en\/a-propos\/nouvelles\/","title":{"rendered":"News"},"content":{"rendered":"\t\t\n\t<div class=\"item component-block-drawers\">\n\t\t<div class=\"container\">\n\t\t\t<div class=\"block-drawers\">\n\t\t\t\t\n\t\t\t\t<ul class=\"block-drawers__list\">\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t<li class=\"block-drawers__item js-a11y-drawer\">\n\t\t\t\t\t\t\t<h3 class=\"block-drawers__heading\" data-a11y-toggle>\n\t\t\t\t\t\t\t\t<button type=\"button\" class=\"block-drawers__trigger\" aria-expanded=\"false\" aria-controls=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-1\">\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__question\">July 28, 2026 &#8211; Aramis Biotechnologies, in collaboration with CIRAIG, Premier Tech and CRIBIQ, is undertaking a large-scale study to evaluate the potential of its plant-based bioproduction platform to reduce the environmental footprint of current technologies.<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__icon\">\n\t\t\t\t\t\t\t\t\t\t<svg width=\"16\" height=\"10\" aria-hidden=\"true\" focusable=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t<use xlink:href=\"#ico-chevron-down\"\/>\n\t\t\t\t\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/button>\n\t\t\t\t\t\t\t<\/h3>\n\n\t\t\t\t\t\t\t<div class=\"wysiwyg block-drawers__panel\" id=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-1\" data-a11y-target hidden>\n\t\t\t\t\t\t\t\t<p><strong><em>Carried out as part of the INNOV-R PME program, this project illustrates Aramis&#8217; commitment to developing more sustainable biosolutions.<\/em><\/strong><\/p>\n<p><strong>Quebec City, Tuesday, July 28, 2026<\/strong> \u2013\u00a0Aramis Biotechnologies Inc. (&#8220;Aramis&#8221;), a pioneering Canadian company and world leader in plant-based biomanufacturing, today announced a collaboration with the International Reference Centre for Life Cycle Assessment and Sustainable Transition (CIRAIG), Premier Tech and the Consortium de recherche et innovations en bio\u00e9conomie industrielle au Qu\u00e9bec (CRIBIQ) to evaluate the ability of its biomanufacturing platform to reduce the environmental impact of current commercial technologies.<\/p>\n<p>At the forefront of environmentally responsible biotechnology, Aramis is developing, in partnership with Premier Tech, a new generation of vertical cultivation systems designed to maximize the benefits of bioproduction in plants and further reduce their environmental footprint.<\/p>\n<p>The partnership with the CIRAIG team will make it possible to evaluate and quantify the reduction in greenhouse gases (GHGs), based on a concrete application of Aramis&#8217; technology. The study will compare the production of seasonal flu vaccines in plants \u2013 grown using Premier Tech&#8217;s Vervio\u2122 vertical cultivation technology, equipped with LED lighting \u2013 with the most widely used commercial method, namely production in embryonated chicken eggs. The CRIBIQ team will coordinate all activities.<\/p>\n<p>&#8220;The promise of our technology is clear: to reduce the environmental impact of bioproduction, while optimizing the production of high-value-added vaccines and proteins. Through this study, we will be able to support this ambition with tangible data, quantify the environmental benefits generated by our platform and demonstrate the full potential of a more sustainable biosolution for vaccines.&#8221; said Audrey Boulianne, Vice President, Biomass Production and Facilities at Aramis.<\/p>\n<p class=\"has-custom-purple-porthos-color has-text-color has-link-color has-small-font-size wp-elements-3 wp-block-paragraph\"><strong>About Aramis Biotechnologies<\/strong><\/p>\n<p>Based in Quebec City, Aramis Biotechnologies is a pioneering Canadian company and world leader in plant-based bioproduction. Through its strategic partnerships, Aramis develops innovative and sustainable biosolutions to meet the evolving needs of industry and society.<\/p>\n<p class=\"has-custom-purple-porthos-color has-text-color has-link-color has-small-font-size wp-elements-5 wp-block-paragraph\"><strong>About INNOV-R PME<\/strong><\/p>\n<p class=\"has-small-font-size wp-block-paragraph\"><a href=\"https:\/\/cribiq.qc.ca\/financement-entreprises\/innov-r\/\">INNOV-R PME\u00a0<\/a>is a government-funded program that aims to enable the realization of innovative industrial research projects with a high potential to reduce greenhouse gases (GHGs) in Quebec, the benefits of which will enable the province to achieve its GHG reduction objectives and targets in the medium and long term. Funded by the Electrification and Climate Change Fund (ECCF) and managed by the Minist\u00e8re de l&#8217;\u00c9conomie, de l&#8217;Innovation et de l&#8217;\u00c9nergie (MEIE), it offers support of up to $450,000. The selected projects must be carried out by a Quebec SME with an eligible partner for the development or improvement of an innovative technology for a maximum period of 2 years.<\/p>\n<p class=\"has-small-font-size wp-block-paragraph\">For more information:<\/p>\n<p class=\"has-small-font-size wp-block-paragraph\"><a href=\"https:\/\/aramisbiotechnologies.com\/\">aramisbiotechnologies.com<\/a><\/p>\n\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t<li class=\"block-drawers__item js-a11y-drawer\">\n\t\t\t\t\t\t\t<h3 class=\"block-drawers__heading\" data-a11y-toggle>\n\t\t\t\t\t\t\t\t<button type=\"button\" class=\"block-drawers__trigger\" aria-expanded=\"false\" aria-controls=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-2\">\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__question\">February 26, 2026 &#8211; Aramis Biotechnologies announces the achievement of an important milestone with the start of a Phase 1\/2 clinical trial of its vaccine in development against seasonal influenza in 728 participants<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__icon\">\n\t\t\t\t\t\t\t\t\t\t<svg width=\"16\" height=\"10\" aria-hidden=\"true\" focusable=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t<use xlink:href=\"#ico-chevron-down\"\/>\n\t\t\t\t\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/button>\n\t\t\t\t\t\t\t<\/h3>\n\n\t\t\t\t\t\t\t<div class=\"wysiwyg block-drawers__panel\" id=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-2\" data-a11y-target hidden>\n\t\t\t\t\t\t\t\t<p class=\"has-figtree-font-family has-small-font-size wp-block-paragraph\"><strong>Quebec City, February 26, 2026<\/strong> \u2013\u00a0Aramis Biotechnologies Inc. (&#8220;Aramis&#8221;), a pioneering Canadian company and world leader in plant-based biomanufacturing, is proud to announce the start of the Phase 1\/2 clinical trial for its trivalent seasonal influenza vaccine in development (&#8220;Aramis vaccine&#8221;).<\/p>\n<p>This new-generation vaccine, produced in plants and unique in the world, aims to diversify the vaccine offer for the population and strengthen protection against influenza, especially in those most at risk. The Aramis vaccine is composed of vaccine particles that mimic the virus and are thus recognized by the immune system, without being infectious.<\/p>\n<p>The randomized Phase 1\/2 trial aims to evaluate the safety and immunogenicity of the Aramis vaccine by comparing it to appropriate commercial vaccines for the 18 to 64 and 65 and older age groups. The clinical trial will be conducted at seven clinical sites across Canada, where 728 healthy volunteers will receive one dose of the Aramis vaccine or a commercially recommended comparator vaccine for each age group.<\/p>\n<p>&#8220;The launch of this study is a significant milestone for Aramis, which we have achieved in a record time of only 18 months since the start of our operations. We are very proud of this accomplishment, which is a testament to the power of our technology and the expertise of our team. Our scientific advances have allowed us to make significant improvements to our platform and our vaccine, the potential of which has been confirmed in preclinical studies. We now look forward to validating these results in humans.&#8221; said Sonia Tr\u00e9panier, Vice President, Preclinical and Clinical Development.<\/p>\n<p>&#8220;We have set ourselves the ambitious goal of becoming the first company to commercialize a human health vaccine manufactured in plants. This milestone marks a key step and a springboard towards the deployment of our platform in different markets, in collaboration with partners,&#8221; adds Fr\u00e9d\u00e9ric Ors, Chief Executive Officer.<\/p>\n<p class=\"has-custom-purple-porthos-color has-text-color has-link-color has-figtree-font-family has-small-font-size wp-elements-2 wp-block-paragraph\"><strong>About Aramis Biotechnologies<\/strong><\/p>\n<p class=\"has-link-color has-figtree-font-family has-small-font-size wp-elements-3 wp-block-paragraph\">Based in Quebec City, Aramis Biotechnologies is a pioneering Canadian company and world leader in plant-based bioproduction. Through its strategic partnerships, Aramis develops innovative and sustainable biosolutions to meet the evolving needs of industry and society.<\/p>\n<p class=\"has-link-color has-figtree-font-family has-small-font-size wp-elements-4 wp-block-paragraph\">For more informations <a href=\"https:\/\/aramisbiotechnologies.com\/\">aramisbiotechnologies.com<\/a><\/p>\n<p class=\"has-figtree-font-family has-small-font-size wp-block-paragraph\"><strong>Media contact<\/strong><br \/>\nNathalie Charland \u2013 Sr. Director, partnerships &amp; communications<br \/>\n<a href=\"mailto:ncharland@aramisbiotechnologies.com\">ncharland@aramisbiotechnologies.com<\/a><\/p>\n\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t<li class=\"block-drawers__item js-a11y-drawer\">\n\t\t\t\t\t\t\t<h3 class=\"block-drawers__heading\" data-a11y-toggle>\n\t\t\t\t\t\t\t\t<button type=\"button\" class=\"block-drawers__trigger\" aria-expanded=\"false\" aria-controls=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-3\">\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__question\">February 10, 2026 &#8211; Aramis Biotechnologies and the Biologics Manufacturing Centre (BMC) Inc. announce the successful delivery of clinical material for the seasonal influenza vaccine in development<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__icon\">\n\t\t\t\t\t\t\t\t\t\t<svg width=\"16\" height=\"10\" aria-hidden=\"true\" focusable=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t<use xlink:href=\"#ico-chevron-down\"\/>\n\t\t\t\t\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/button>\n\t\t\t\t\t\t\t<\/h3>\n\n\t\t\t\t\t\t\t<div class=\"wysiwyg block-drawers__panel\" id=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-3\" data-a11y-target hidden>\n\t\t\t\t\t\t\t\t<p><strong><em>Formulation and aseptic filling successfully completed for the phase 1\/2 clinical study of Aramis Biotechnologies&#8217; vaccine<\/em><\/strong><\/p>\n<p class=\"has-small-font-size wp-block-paragraph\"><strong>Montreal and Quebec City, Tuesday February 10, 2026<\/strong> \u2013\u00a0Aramis Biotechnologies Inc. (&#8220;Aramis&#8221;), a pioneering Canadian company and world leader in plant biomanufacturing, and the Biologics Manufacturing Centre (BMC) Inc., a not-for-profit organization specializing in the manufacture of essential biopharmaceutical solutions, today announced the <strong>successful completion of the formulation, aseptic filling and clinical packaging activities<\/strong> of Aramis&#8217; seasonal influenza vaccine in development for its Phase 1\/2 clinical study.<\/p>\n<p>This key milestone marks the operational culmination of the partnership announced in February 2025 between the two organizations. The BMC leveraged its expertise in formulation, aseptic filling operations and clinical packaging to ensure the production of clinical material that complies with the quality, safety and regulatory compliance requirements applicable to clinical trials.<\/p>\n<p>The successful delivery of this clinical material is an important step forward for the Aramis seasonal influenza vaccine development program, a product with the potential to improve the protection of the most at-risk populations. It also illustrates the role of the BMC within the Canadian biopharmaceutical ecosystem in supporting innovative projects, from science to clinical manufacturing.<\/p>\n<p>&#8220;We are extremely satisfied with our partnership with the BMC. Aramis&#8217; business strategy is based on the complementarity of expertise. The BMC&#8217;s specialists, facilities and pharmaceutical production equipment fully met our needs,&#8221; said Fr\u00e9d\u00e9ric Ors, Chief Executive Officer of Aramis. &#8220;We collaborated with a motivated and competent team, which delivered high-quality work, in accordance with our expectations and those of the regulatory authorities.&#8221;<\/p>\n<p>&#8220;This achievement marks an important milestone for Aramis and we look forward to continuing our discussions with the BMC to expand our collaboration,&#8221; continued Nicolas Petit, Aramis&#8217; Chief Operating Officer.<\/p>\n<p>For the BMC, this achievement confirms its role as a strategic partner for Canadian biotechnology companies in clinical development, by offering integrated formulation and aseptic filling services tailored to high value-added biologics.<\/p>\n<p>&#8220;The success of this project illustrates the value of close collaboration between an innovative biotech company and an agile manufacturing partner. We are proud to have delivered clinical material that is compliant, on time and to the highest quality standards,&#8221; said Andy Sheldon, CEO of the Biologics Manufacturing Centre (BMC) Inc.<\/p>\n<p>This partnership between Aramis Biotechnologies and the BMC is a success and demonstrates a promising first collaboration, paving the way for future joint initiatives. It illustrates the ability of the two organizations to combine their expertise in order to effectively support the clinical development of innovative biopharmaceutical solutions.<\/p>\n<p>&nbsp;<\/p>\n<p class=\"has-custom-purple-porthos-color has-text-color has-link-color has-small-font-size wp-elements-3 wp-block-paragraph\"><strong>About Aramis Biotechnologies<\/strong><\/p>\n<p class=\"has-link-color has-figtree-font-family has-small-font-size wp-elements-3 wp-block-paragraph\">Based in Quebec City, Aramis Biotechnologies is a pioneering Canadian company and world leader in plant-based bioproduction. Through its strategic partnerships, Aramis develops innovative and sustainable biosolutions to meet the evolving needs of industry and society.<\/p>\n<p class=\"has-custom-purple-porthos-color has-text-color has-link-color has-figtree-font-family has-small-font-size wp-elements-5 wp-block-paragraph\"><strong>About the Biologics Manufacturing Centre<\/strong><\/p>\n<p>Based in Town of Mount Royal, the BMC is a non-profit organization dedicated to the production of innovative biologic solutions. Its mission is to facilitate access to quality, affordable, and sustainable biologic therapies, while fostering innovation in rare and infectious diseases. The BMC is committed to building a robust and collaborative ecosystem to build resilience in the face of emerging health threats and promote health equity.<\/p>\n<p class=\"has-small-font-size wp-block-paragraph\">For more information:<\/p>\n<p class=\"has-small-font-size wp-block-paragraph\"><a href=\"https:\/\/aramisbiotechnologies.com\/\">aramisbiotechnologies.com<\/a><\/p>\n<p class=\"has-small-font-size wp-block-paragraph\"><a href=\"https:\/\/bmc-cppb.ca\/?gad_source=1&amp;gad_campaignid=22756437270&amp;gclid=CjwKCAjwrbfWBhAeEiwAc2e6Pvktk8oIp4nZxT_csg0hCslTDAPHnIFn0LHZiudSWciDe0_COTLOihoCcJoQAvD_BwE\">BMC<\/a><\/p>\n\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t<li class=\"block-drawers__item js-a11y-drawer\">\n\t\t\t\t\t\t\t<h3 class=\"block-drawers__heading\" data-a11y-toggle>\n\t\t\t\t\t\t\t\t<button type=\"button\" class=\"block-drawers__trigger\" aria-expanded=\"false\" aria-controls=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-4\">\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__question\">June 12, 2025 &#8211; Aramis Biotechnologies unveils major advances for protein production in plants at its inaugural &#8220;Aramis Scientific Horizon&#8221; event<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__icon\">\n\t\t\t\t\t\t\t\t\t\t<svg width=\"16\" height=\"10\" aria-hidden=\"true\" focusable=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t<use xlink:href=\"#ico-chevron-down\"\/>\n\t\t\t\t\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/button>\n\t\t\t\t\t\t\t<\/h3>\n\n\t\t\t\t\t\t\t<div class=\"wysiwyg block-drawers__panel\" id=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-4\" data-a11y-target hidden>\n\t\t\t\t\t\t\t\t<p class=\"has-text-align-justify has-figtree-font-family wp-block-paragraph\"><strong>Quebec City, Thursday June 12, 2025<\/strong> \u2013 Aramis Biotechnologies Inc. (&#8220;Aramis&#8221;), a Quebec-based company specializing in the production of innovative plant-based vaccines, proudly announces a series of scientific breakthroughs, unveiled at the very first edition of its annual<em> Aramis Scientific Horizon event<\/em>. These advances were achieved in just 12 months, underscoring Aramis&#8217; commitment to rapid, high-impact innovation. These innovations mark a strategic turning point for Aramis, with the potential for major repercussions, both for plant production and the commercialization of Aramis&#8217; first product.<\/p>\n<p><strong>Main scientific advances:<\/strong><\/p>\n<p><strong>1. Yield multiplication<\/strong><\/p>\n<p>Aramis&#8217; next-generation platform has demonstrated a remarkable increase in yield, setting a new benchmark in the plant biomanufacturing industry.<\/p>\n<p><strong>2. Next-generation vertical growing system<\/strong><\/p>\n<p>By replacing greenhouse cultivation with a proprietary vertical production system, Aramis has improved the control, reproducibility and quality of biomass \u2013 enabling production that can be exported anywhere in the world.<\/p>\n<p><strong>3. Simplifying business scaling<\/strong><\/p>\n<p>The new high-throughput platform eliminates the need for scaling for commercial production, speeding up development and reducing costs.<\/p>\n<p><strong>4. Promising preclinical results<\/strong><\/p>\n<p>Aramis&#8217; next-generation seasonal influenza vaccine candidate based on vaccine particles (VLP) has demonstrated convincing results in preclinical studies, compared to alternatives currently on the market.<\/p>\n<p>&#8220;Aramis was founded with a clear vision: to build a robust and scalable platform that accelerates the journey from scientific discovery to commercialization. With today&#8217;s results, our vision becomes reality,&#8221; said Mr. Fr\u00e9d\u00e9ric Ors, Chief Executive Officer of Aramis.<\/p>\n<p>&#8220;The exceptional yields achieved mean that the scale of Aramis&#8217; current process used for clinical studies and meeting Good Manufacturing Practices (GMP) is already sufficient to support a commercial vaccine launch \u2013 eliminating the need for scale-up. In the world of biomanufacturing, this is a defining advantage and a decisive win. \u00bb<\/p>\n<p>Dr. Marc-Andr\u00e9 D&#8217;Aoust, Chief Scientific Officer of Aramis, added: &#8220;Vaccine particles are among the most effective vaccine technologies, mimicking natural immunization without live pathogens. While VLPs are commercially successful, broader applications have been limited by biomanufacturing challenges. Our plant-based production platform overcomes these hurdles, enabling the full potential of VLP-based influenza vaccines to be harnessed.&#8221; \u00bb<\/p>\n<p class=\"has-text-align-justify has-figtree-font-family wp-block-paragraph\">&#8220;Our influenza vaccine candidate is designed to address a significant unmet medical need to protect vulnerable populations from influenza \u2013 particularly the elderly \u2013 by prolonging protection and enhancing the immune response,&#8221; continued Dr. D&#8217;Aoust. &#8220;We look forward to initiating our Phase 1 and Phase 2 controlled clinical trials in the first quarter of 2026.&#8221;<\/p>\n<p class=\"has-custom-purple-porthos-color has-text-color has-link-color has-figtree-font-family wp-elements-2 wp-block-paragraph\"><strong>About Aramis Biotechnologies<\/strong><\/p>\n<p>Based in Quebec City, Aramis Biotechnologies is a Canadian company founded in 2023 that specializes in the production of innovative plant-based vaccines. As a company with majority ownership of employee-shareholders, Aramis&#8217; ambition is to develop innovative and sustainable solutions to current and future public health challenges. The Aramis team is grateful for the support provided by Innovation, Science and Economic Development Canada, the City of Quebec and its group of private investors.<\/p>\n<p class=\"has-link-color has-figtree-font-family wp-elements-5 wp-block-paragraph\">For more information:<\/p>\n<p class=\"has-link-color has-figtree-font-family wp-elements-6 wp-block-paragraph\"><a href=\"https:\/\/aramisbiotechnologies.com\/\">aramisbiotechnologies.com<\/a><\/p>\n\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t<li class=\"block-drawers__item js-a11y-drawer\">\n\t\t\t\t\t\t\t<h3 class=\"block-drawers__heading\" data-a11y-toggle>\n\t\t\t\t\t\t\t\t<button type=\"button\" class=\"block-drawers__trigger\" aria-expanded=\"false\" aria-controls=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-5\">\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__question\">March 19, 2025 &#8211; Aramis Biotechnologies welcomes a world-class board of directors to propel its development<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__icon\">\n\t\t\t\t\t\t\t\t\t\t<svg width=\"16\" height=\"10\" aria-hidden=\"true\" focusable=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t<use xlink:href=\"#ico-chevron-down\"\/>\n\t\t\t\t\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/button>\n\t\t\t\t\t\t\t<\/h3>\n\n\t\t\t\t\t\t\t<div class=\"wysiwyg block-drawers__panel\" id=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-5\" data-a11y-target hidden>\n\t\t\t\t\t\t\t\t<p><strong><em>Comprised of recognized leaders in the fields of life sciences, corporate affairs and finance, this board is ready to guide Aramis to new heights.<\/em><\/strong><\/p>\n<p>&nbsp;<\/p>\n<p class=\"gt-block has-text-align-justify has-small-font-size wp-block-paragraph\"><strong>Quebec City, March 19, 2025 <\/strong>Aramis Biotechnologies Inc. (&#8220;Aramis&#8221;), a Quebec City-based company specialized in plant-based biomanufacturing of innovative vaccines, is proud to announce its new Board of Directors, composed of eminent and experienced professionals in various fields of life sciences, especially vaccines, corporate affairs and finance. This board will play a crucial role in the governance of the company and in achieving its strategic objectives.<\/p>\n<p class=\"has-text-align-justify has-small-font-size wp-block-paragraph\">&#8220;We are delighted to welcome these experts to our Board of Directors. Their wealth of experience and in-depth knowledge will be invaluable assets to Aramis,&#8221; said Fr\u00e9d\u00e9ric Ors, Co-Founder and CEO of Aramis. &#8220;We are confident that their strategic vision and expertise will strengthen our position in the vaccine market and drive our long-term growth.&#8221;<\/p>\n<p class=\"has-text-align-justify has-small-font-size wp-block-paragraph\">The members of the Board of Directors are:<\/p>\n<p class=\"gt-block has-small-font-size wp-block-paragraph\"><strong>Mr. Pierre Labb\u00e9, Chairman of the Board of Directors<\/strong><\/p>\n<p class=\"has-text-align-justify has-small-font-size wp-block-paragraph\">Mr. Labb\u00e9 is currently Executive Vice President of Finance at QScale, an innovative company specializing in eco-friendly data centres. Prior to joining QScale, Mr. Labb\u00e9 held senior financial positions at IMV Inc., LeddarTech Inc., and Medicago Inc. He has over 30 years of experience in financial leadership.<\/p>\n<p class=\"has-text-align-justify has-small-font-size wp-block-paragraph\">At QScale, Pierre Labb\u00e9 oversees financial strategy, investor relations, financial reporting, tax, treasury and risk management. He played a key role in securing $320M in financing to accelerate the company&#8217;s growth. Mr. Labb\u00e9 is also a member of the Quebec\u2019s Chartered Professional Accountants and of the Institute of Corporate Directors.<\/p>\n<p class=\"gt-block has-small-font-size wp-block-paragraph\"><strong>Mrs. Brigitte Barbeau, Director<\/strong><\/p>\n<p class=\"has-text-align-justify has-small-font-size wp-block-paragraph\">Mrs. Barbeau served as Vice President of International Quality at Sanofi Pasteur, where she oversaw quality and compliance standards for pharmaceutical products globally. She also worked for Medicago as Chief Compliance Officer, contributing to the improvement of vaccine compliance and safety processes. She was also Quality Director at GSK, where she was responsible for quality control and assurance for the vaccine production sites in Laval and Quebec City.<\/p>\n<p class=\"has-text-align-justify has-small-font-size wp-block-paragraph\">With a strong background in biopharmaceuticals, Good Manufacturing Practices and vaccines, Mrs. Barbeau is now an independent consultant, bringing her expertise to various companies in the pharmaceutical sector.<\/p>\n<p class=\"gt-block has-small-font-size wp-block-paragraph\"><strong>Mr. Tony D&#8217;Amore, Director<\/strong><\/p>\n<p class=\"has-text-align-justify has-small-font-size wp-block-paragraph\">Mr. D&#8217;Amore was a key player in the field of research and product development at Sanofi Pasteur. He has held several leadership positions, including Vice President of Global Research and Product Development.<\/p>\n<p class=\"has-text-align-justify has-small-font-size wp-block-paragraph\">During his tenure, he oversaw the development of processes and analyses for the manufacturing of clinical materials, supporting numerous clinical trials. He has led a team of more than 600 people around the world and has played a crucial role in optimizing manufacturing processes and implementing new technologies.<\/p>\n<p class=\"has-text-align-justify has-small-font-size wp-block-paragraph\">Mr. D&#8217;Amore is also recognized for his expertise in bioprocesses and vaccine development, having contributed to innovation and accelerated product development timelines. Since his departure from Sanofi, he has continued to share his expertise as a consultant and member of scientific advisory boards.<\/p>\n<p class=\"gt-block has-small-font-size wp-block-paragraph\"><strong>Mr. Serge Ferland, Director<\/strong><\/p>\n<p class=\"has-text-align-justify has-small-font-size wp-block-paragraph\">Mr. Ferland is an experienced businessman who is involved in his community. He has worked in the food industry for many years, during which he sat on the board of directors of Metro and was president of Serro Food Inc., Claka Supermarket Inc. and Slow Cow.<\/p>\n<p class=\"has-text-align-justify has-small-font-size wp-block-paragraph\">With nearly 40 years of experience, Mr. Ferland has distinguished himself through his community involvement and innovative initiatives. In addition to his responsibilities at Metro, he was Chairman of the Board of Directors of the Soci\u00e9t\u00e9 du Centre des Congr\u00e8s de Qu\u00e9bec and the SportAccord Congress. Mr. Ferland holds a bachelor&#8217;s degree in administration and a bachelor&#8217;s degree in accounting from Laval University.<\/p>\n<p class=\"gt-block has-small-font-size wp-block-paragraph\"><strong>Mr. Paul Marshall, Director<\/strong><\/p>\n<p class=\"has-text-align-justify has-small-font-size wp-block-paragraph\">Mr. Marshall has been an influential leader in the biopharmaceutical industry, having held leadership positions at Amgen and Baxter, among others. He has overseen international teams and contributed to the optimization of manufacturing processes and technological innovation. He has played a key role in product development and technical operations, helping to improve the efficacy and quality of biopharmaceuticals. His expertise in bioprocesses and vaccine development has been critical to innovation and accelerating product development timelines.<\/p>\n<p class=\"has-text-align-justify has-small-font-size wp-block-paragraph\">Mr. Marshall is also an Assistant Professor of Human Anatomy and Physiology at the New Hampshire Technical Institute, a member of the Dean\u2019s advisory board for the College of Arts and Sciences at University of Massachusetts at Dartmouth, and President of the consulting firm Marshall Biopharm Associates, LLC.<\/p>\n<p class=\"gt-block has-small-font-size wp-block-paragraph\"><strong>Mr. Fran\u00e7ois Provencher, Observer<\/strong><\/p>\n<p class=\"has-text-align-justify has-small-font-size wp-block-paragraph\">Mr. Provencher founded one of the first financial planning and portfolio management firms focused on retirees, which was acquired in 1998 by a subsidiary of the National Bank. He then worked as vice-president with National Bank Financial as a portfolio manager and was a key player in the wealth management field. Having received numerous distinctions with his team, including Investment Advisor of the Year in Canada, Mr. Provencher has also distinguished himself by his commitment to the business community, helping several early-stage technology companies in Quebec raise capital to promote their growth over the past 20 years.<\/p>\n<p class=\"gt-block has-custom-purple-porthos-color has-text-color has-link-color has-small-font-size wp-elements-3 wp-block-paragraph\"><strong>About Aramis Biotechnologies<\/strong><\/p>\n<p class=\"has-text-align-justify has-link-color has-small-font-size wp-elements-4 wp-block-paragraph\">Based in Quebec City, Aramis Biotechnologies is a Canadian company founded in 2023 that specializes in plant-based production of innovative vaccines. As a majority employee-owned company, Aramis\u2019 ambition is to develop innovative and sustainable solutions to current and future public health challenges.\u202fThe Aramis&#8217; team is grateful for the support from Innovation, Sciences and Economic Development Canada, from the City of Quebec and from its group of private investors.<\/p>\n<div class=\"wp-block-spacer\" aria-hidden=\"true\"><\/div>\n<p class=\"has-small-font-size wp-block-paragraph\">For more information:<\/p>\n<p class=\"gt-block has-small-font-size wp-block-paragraph\"><a href=\"https:\/\/aramisbiotechnologies.com\/en\/\">aramisbiotechnologies.com<\/a><\/p>\n\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t<li class=\"block-drawers__item js-a11y-drawer\">\n\t\t\t\t\t\t\t<h3 class=\"block-drawers__heading\" data-a11y-toggle>\n\t\t\t\t\t\t\t\t<button type=\"button\" class=\"block-drawers__trigger\" aria-expanded=\"false\" aria-controls=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-6\">\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__question\">February 21, 2025 &#8211; CQDM, IVADO and three Quebec companies invest $2M to accelerate the development of highly targeted and less toxic cancer therapies using AI<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__icon\">\n\t\t\t\t\t\t\t\t\t\t<svg width=\"16\" height=\"10\" aria-hidden=\"true\" focusable=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t<use xlink:href=\"#ico-chevron-down\"\/>\n\t\t\t\t\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/button>\n\t\t\t\t\t\t\t<\/h3>\n\n\t\t\t\t\t\t\t<div class=\"wysiwyg block-drawers__panel\" id=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-6\" data-a11y-target hidden>\n\t\t\t\t\t\t\t\t<div class=\"entry-content\">\n<p class=\"wp-block-paragraph\"><strong>Montreal, February 21, 2025 \u2013<\/strong> CQDM is pleased to announce the funding of a collaborative research project aimed at developing new tumor-specific therapeutic candidates designed to minimize toxicities and side effects of oncology therapies, using an innovative approach based on artificial intelligence (AI).\u00a0 This project, worth a total of $2,056,964, is being carried out jointly by 9Bio Therapeutics, Molecular Forecaster and Aramis Biotechnologies, three Quebec-based companies. Funding for this project is made possible thanks to a $1,028,482 grant from the Government of Quebec awarded by CQDM as part of the PARTENAR-IA program carried out in partnership with IVADO.<\/p>\n<p class=\"wp-block-paragraph\">Many cancer therapies have significant side effects, impacting quality of life and leading up to 32% of patients<sup> (<\/sup><sup>1)<\/sup> to discontinue their treatment or opt for less effective alternatives, according to a recent study. With the aim of reducing harmful side effects, Molecular Forecaster and 9Bio will use AI to rapidly analyze large datasets and predict molecular interactions.\u00a0 Two distinct new targeted therapies with the potential to act complementarily will be developed in parallel. On the one hand, Molecular Forecaster, will deploy its biophysics-based approach, bolstered by machine learning models, to generate small molecules specifically targeting tumor cells, while 9Bio will mobilize its structural biology and AI know-how to generate more targeted and effective monoclonal antibodies. Thanks to AI, they will be able to evaluate the physio-chemical properties of new therapeutic candidates up to 8 months faster, in the research and development (R&amp;D) phase, while reducing costs by 30% compared with traditional laboratory approaches. These biologics will then be manufactured by Aramis Biotechnologies using its versatile plant-based production platform.<\/p>\n<p class=\"wp-block-paragraph\">This collaborative research project spans from discovery to early proof-of-concept for these innovative therapies, which have the potential to be better tolerated, improve quality of life, and make them more accessible to a wider range of cancer patients.<\/p>\n<p class=\"wp-block-paragraph\"><strong>Reference: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/strong><br \/>\n<a href=\"https:\/\/www.ejcancer.com\/article\/S0959-8049(24)00679-8\/fulltext\" target=\"_blank\" rel=\"noopener\" data-type=\"link\" data-id=\"https:\/\/www.ejcancer.com\/article\/S0959-8049(24)00679-8\/fulltext\">(1) Holmstroem et al., Eur J. Cancer, 2024[CG1]\u00a0<\/a><\/p>\n<p class=\"wp-block-paragraph\"><em>\u201cInnovating in life sciences is key to improving the care provided to the population. I\u2019m especially proud of our government supporting such collaborative research projects that leverage AI and demonstrate the expertise of our researchers and the strength of our innovation ecosystem,\u201d<\/em> said Christopher Skeete, Minister for the Economy, Minister Responsible for the Fight Against Racism and Minister Responsible for the Laval Region.<\/p>\n<p class=\"wp-block-paragraph\"><em>\u201cBy encouraging collaboration between innovative businesses and the research sector, we are accelerating the integration of responsible AI into society and positioning Qu\u00e9bec as a leader in this industry. This collaborative research project is a great example. In addition to helping three partner companies grow, it represents a major scientific advance for patients with cancer,\u201d<\/em> said C\u00e9line\u00a0Haytayan, Member for Laval-des-Rapides, Parliamentary Assistant to the Minister of International Relations and La Francophonie, and Parliamentary Assistant to the Minister of Economy, Innovation and Energy (AI component).<\/p>\n<p class=\"wp-block-paragraph\">\n\u201c<em>We are proud to support this project, which uses artificial intelligence to accelerate the discovery and access to clinical trials of innovative cancer treatments. By combining their complementary expertise, 9Bio Therapeutics, Molecular Forecaster and Aramis Biotechnologies are paving the way for more specific, less toxic therapies accessible to more patients. This initiative responds to crucial challenges in oncology and is a testament to Quebec\u2019s excellence in biotechnology and artificial intelligence.<\/em>\u201d, says Diane Gosselin, President and CEO of CQDM.<\/p>\n<p class=\"wp-block-paragraph\"><em>\u201cThis initiative is an incredible hope for thousands of patients. IVADO is extremely proud to support, in collaboration with CQDM, 9Bio Therapeutics, Molecular Forecaster, and Aramis Biotechnologies in this collaborative research project through PARTENAR-IA, proving that artificial intelligence offers exceptional opportunities for biotechnology players in Quebec, as well as for the well-being of populations,\u201d<\/em> adds Nancy Laram\u00e9e, Director of Partnerships at IVADO.<\/p>\n<p class=\"wp-block-paragraph\"><strong>About 9Bio Therapeutics<\/strong><\/p>\n<p>9Bio Therapeutics is a biotech company committed to oncology therapeutics development. Their AI-guided structural biology platform integrates anatomical and biochemical contexts to design drugs that selectively target tumors. Using this approach, they generate medicines with specificity for tumors that spare healthy tissues, improving safety, efficacy, and opening the door to previously underexploited therapeutic modalities. Their pipeline includes three discovery-stage therapies: an antibody-drug conjugate (ADC) targeting tumor cells, an ADC targeting tumor-subverted immune cells, and an engineered cytokine. Learn more at <a href=\"https:\/\/9bio.ca\/\" target=\"_blank\" rel=\"noopener\">https:\/\/9bio.ca\/<\/a>.<\/p>\n<p class=\"wp-block-paragraph\">\n<p class=\"wp-block-paragraph\"><strong>About Aramis Biotechnologies<\/strong><\/p>\n<p>Based in Quebec City, Aramis Biotechnologies is a Canadian company founded in 2023 that specializes in plant-based production of innovative vaccines. As a majority employee-owned company, Aramis\u2019 ambition is to develop innovative and sustainable solutions to current and future public health challenges.\u202fThe Aramis\u2019 team is grateful for the support from Innovation, Sciences and Economic Development Canada, from the City of Quebec and from its group of private investors. Learn more at <a href=\"https:\/\/aramisbiotechnologies.com\/en\/\" target=\"_blank\" rel=\"noopener\">https:\/\/aramisbiotechnologies.com\/en\/<\/a>.<\/p>\n<p class=\"wp-block-paragraph\">\n<p class=\"wp-block-paragraph\"><strong>About CQDM<\/strong><\/p>\n<p class=\"wp-block-paragraph\"><em>Biopharma Innovation Facilitator<br \/>\n<\/em>CQDM is a not-for-profit biopharmaceutical research consortium whose mission is to support and facilitate collaborative multi-stakeholder research and development aimed at accelerating the translation or transformation of innovative technologies into solutions to unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. For more information, consult our website\u00a0 <a href=\"https:\/\/cqdm.org\/en\/\">https:\/\/cqdm.org\/en\/<\/a> and join us on Twitter\/X <a href=\"https:\/\/x.com\/CQDM_Canada\">@CQDM_Canada<\/a> and <a href=\"https:\/\/www.linkedin.com\/company\/cqdm\/\" target=\"_blank\" rel=\"noopener\">LinkedIn.<\/a><\/p>\n<p class=\"wp-block-paragraph\"><strong>Partenar-IA <\/strong>is a program providing direct support to Quebec companies for collaborative biopharmaceutical R&amp;D projects based on artificial intelligence and applicable to the biopharmaceutical sector.<\/p>\n<p class=\"wp-block-paragraph\"><strong>About IVADO<\/strong><\/p>\n<p class=\"wp-block-paragraph\">IVADO is an interdisciplinary, cross-sectoral research and knowledge mobilization consortium whose mission is to develop and promote a robust, reasoning and responsible AI. Led by Universit\u00e9 de Montr\u00e9al with four university partners (Polytechnique Montr\u00e9al, HEC Montr\u00e9al, Universit\u00e9 Laval and McGill University), IVADO brings together research centers, government bodies and industry members to co-build ambitious cross-sectoral initiatives with the goal of fostering a paradigm shift for AI and its adoption. For more information, please visit our website at <a href=\"https:\/\/ivado.ca\/en\/\" target=\"_blank\" rel=\"noopener\">https:\/\/ivado.ca\/en\/<\/a>.<\/p>\n<p class=\"wp-block-paragraph\">\n<p class=\"wp-block-paragraph\">\n<strong>About Molecular Forecaster<\/strong><\/p>\n<p>Molecular Forecaster Inc. (MFI) is helping organizations make smarter decisions in small molecule drug design. MFI uses a highly collaborative research-as-a-service to transform data into insight to accelerate preclinical pharmaceutical programs around the world. The company is a go-to partner in small molecule drug design, combining proprietary tools and technology, expertise and know-how, and an all-in approach to collaboration to advance only the best shots on goal. Learn more at <a href=\"https:\/\/molecularforecaster.com\/\" target=\"_blank\" rel=\"noopener\">https:\/\/molecularforecaster.com\/<\/a><\/p>\n<p class=\"wp-block-paragraph\">\n<p class=\"wp-block-paragraph\"><strong>Media Contact:<\/strong><\/p>\n<p class=\"wp-block-paragraph\">Julia Serafino \u2013 CQDM Marketing and Communications Manager<br \/>\n438-543-9498<br \/>\n<a href=\"mailto:jserafino@cqdm.org\">jserafino@cqdm.org<\/a><\/p>\n<\/div>\n\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t<li class=\"block-drawers__item js-a11y-drawer\">\n\t\t\t\t\t\t\t<h3 class=\"block-drawers__heading\" data-a11y-toggle>\n\t\t\t\t\t\t\t\t<button type=\"button\" class=\"block-drawers__trigger\" aria-expanded=\"false\" aria-controls=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-7\">\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__question\">February 14, 2025 &#8211; Aramis Biotechnologies and the Biologics Manufacturing Centre announce a partnership<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__icon\">\n\t\t\t\t\t\t\t\t\t\t<svg width=\"16\" height=\"10\" aria-hidden=\"true\" focusable=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t<use xlink:href=\"#ico-chevron-down\"\/>\n\t\t\t\t\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/button>\n\t\t\t\t\t\t\t<\/h3>\n\n\t\t\t\t\t\t\t<div class=\"wysiwyg block-drawers__panel\" id=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-7\" data-a11y-target hidden>\n\t\t\t\t\t\t\t\t<p class=\"gt-block has-text-align-center has-custom-green-bench-color has-text-color has-link-color has-small-font-size wp-elements-2 wp-block-paragraph\"><em><strong>Agreement on Formulation and Finish of a Virus-Like Particle Vaccine for Phase 1 and 2 Clinical Trials<\/strong><\/em><\/p>\n<p>&nbsp;<\/p>\n<p class=\"gt-block has-text-align-justify has-small-font-size wp-block-paragraph\"><strong>Montreal and Quebec, Friday, February 14, 2025<\/strong>\u2013 Aramis Biotechnologies Inc. (\u201cAramis\u201d), a Quebec company specializing in the production of innovative vaccines produced in plants, and the Biologics Manufacturing Centre (BMC), a non-profit organization specializing in the manufacturing of essential biopharmaceutical solutions, are pleased to announce the signing of a strategic agreement.<\/p>\n<p class=\"has-small-font-size wp-block-paragraph\">This partnership will leverage the expertise of both organizations to ensure the efficient formulation and finish of clinical materials for Aramis&#8217; seasonal influenza vaccine candidate, a product with the potential to enhance protection against the virus among high-risk populations.<\/p>\n<p class=\"has-text-align-justify has-small-font-size wp-block-paragraph\">Under the terms of the agreement, BMC will provide formulation and finish services for vials of Aramis&#8217; vaccine candidate in preparation for its upcoming Phase 1 and 2 clinical trials. This collaboration represents a significant milestone in the inaugural partnership between Aramis and BMC, combining cutting-edge science with manufacturing excellence to support clinical development success.<\/p>\n<p class=\"has-text-align-justify has-small-font-size wp-block-paragraph\">&#8220;We are thrilled to collaborate with BMC as our partner for the formulation and finish of our clinical materials,&#8221; said Fr\u00e9d\u00e9ric Ors, Co-founder and CEO of Aramis. &#8220;This partnership aligns with Aramis&#8217; business model of leveraging the best the best skills and capabilities available through partners for the production of its vaccines. It highlights the strength and diversity of Canada&#8217;s vaccine production ecosystem and its capacity to respond to potential pandemics. With this first collaboration, we can rely on a synergy of expertise and a shared commitment to collaboration and quality across our organizations.&#8221;<\/p>\n<p class=\"has-small-font-size wp-block-paragraph\">Isabelle Caron, President and Chief Executive Officer of BMC, emphasized the importance of this collaboration:<\/p>\n<p class=\"has-small-font-size wp-block-paragraph\">&#8220;We are excited to partner with Aramis Biotechnologies to support the formulation and finish of their influenza vaccine candidate. This partnership aligns seamlessly with BMC\u2019s mission to foster Canadian biopharmaceutical innovation and improve access to cutting-edge health solutions. Together, we are building a strong and resilient local life sciences ecosystem equipped to address today\u2019s and tomorrow\u2019s public health challenges.&#8221;<\/p>\n<div class=\"wp-block-spacer\" aria-hidden=\"true\"><\/div>\n<p class=\"gt-block has-custom-purple-porthos-color has-text-color has-link-color has-small-font-size wp-elements-3 wp-block-paragraph\"><strong>About Aramis Biotechnologies<\/strong><\/p>\n<p class=\"has-text-align-justify has-link-color has-small-font-size wp-elements-4 wp-block-paragraph\">Based in Quebec City, Aramis Biotechnologies is a Canadian company founded in 2023 that specializes in plant-based production of innovative vaccines. As a majority employee-owned company, our ambition is to develop innovative and sustainable solutions to current and future public health challenges.\u202fThe Aramis&#8217; team is grateful for the support from Innovation, Sciences and Economic Development Canada, from the City of Quebec and from its group of private investors.<\/p>\n<p class=\"gt-block has-custom-purple-porthos-color has-text-color has-link-color has-small-font-size wp-elements-5 wp-block-paragraph\"><strong>About the Biologics Manufacturing Centre<\/strong><\/p>\n<p class=\"has-small-font-size wp-block-paragraph\">Located in Ville Mont-Royal, the Biologics Manufacturing Centre (BMC) is a non-for-profit organization dedicated to the production of innovative biological solutions. Its mission is to facilitate access to high-quality, affordable, and sustainable biological therapies while fostering innovation in rare and infectious diseases. BMC is committed to building a robust and collaborative ecosystem to strengthen resilience against emerging health threats and promote health equity.<\/p>\n<div class=\"wp-block-spacer\" aria-hidden=\"true\"><\/div>\n<p class=\"has-small-font-size wp-block-paragraph\">For more information:<\/p>\n<p class=\"gt-block has-small-font-size wp-block-paragraph\"><a href=\"https:\/\/aramisbiotechnologies.com\/en\/\">aramisbiotechnologies.com<\/a><\/p>\n<p class=\"gt-block has-small-font-size wp-block-paragraph\"><a href=\"https:\/\/bmc-cppb.ca\/fr\/accueil\/\">BMC<\/a><\/p>\n\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t<li class=\"block-drawers__item js-a11y-drawer\">\n\t\t\t\t\t\t\t<h3 class=\"block-drawers__heading\" data-a11y-toggle>\n\t\t\t\t\t\t\t\t<button type=\"button\" class=\"block-drawers__trigger\" aria-expanded=\"false\" aria-controls=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-8\">\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__question\">December 17, 2024 &#8211; Aramis Biotechnologies and Biodextris announce a partnership<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__icon\">\n\t\t\t\t\t\t\t\t\t\t<svg width=\"16\" height=\"10\" aria-hidden=\"true\" focusable=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t<use xlink:href=\"#ico-chevron-down\"\/>\n\t\t\t\t\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/button>\n\t\t\t\t\t\t\t<\/h3>\n\n\t\t\t\t\t\t\t<div class=\"wysiwyg block-drawers__panel\" id=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-8\" data-a11y-target hidden>\n\t\t\t\t\t\t\t\t<p><strong>Downstream manufacturing agreement for virus-like particle vaccine for Phase 1 and 2 clinical trials<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>QUEBEC CITY, Dec. 17, 2024 &#8211; Aramis Biotechnologies Inc. (&#8220;Aramis&#8221;), a Quebec City-based company specializing in the production of innovative plant-based vaccines, and Biodextris Inc. (&#8220;Biodextris&#8221;), a Montreal-based CDMO specializing in complex GMP-compliant biologics, are pleased to announce the signing of an agreement. This strategic partnership will leverage the expertise of both companies to ensure efficient downstream manufacturing of clinical material for Aramis&#8217; lead product candidate, a seasonal influenza vaccine with the potential to enhance the protection of at-risk populations.<\/p>\n<p>Under the terms of the agreement, Biodextris will provide Aramis with access to its state-of-the-art facilities and industry-leading capabilities to ensure the timely production of high-quality material for Aramis&#8217; upcoming Phase 1 and 2 clinical trials. The downstream manufacturing agreement marks an important milestone in the ongoing collaboration between Aramis and Biodextris, combining cutting-edge science and manufacturing excellence to ensure clinical development success.<\/p>\n<p>&#8220;We are delighted to be working with Biodextris as a partner for downstream manufacturing and clinical material supply,&#8221; said Fr\u00e9d\u00e9ric Ors, Co-Founder and CEO of Aramis. &#8220;This partnership is in line with Aramis&#8217; business model of using the best external skills and capabilities, and preparing for the scale-up of operations in preparation for an eventual pandemic response. From the initial proposal to the extensive collaboration to date, we have been impressed by Biodextris&#8217; partnership-centric approach to identifying and solving technical challenges, as well as its commitment to the highest quality standards, making it an ideal partner for the clinical-scale production of our influenza vaccine candidate.&#8221; \u00bb<\/p>\n<p>&#8220;It is a pleasure to be chosen as Aramis&#8217; downstream development and manufacturing partner in its mission to revolutionize vaccines,&#8221; says C\u00e9dric H\u00e9roux, Chief Executive Officer of Biodextris. &#8220;The Aramis team&#8217;s deep scientific expertise and passion for health impact, both in Canada and globally, has resonated deeply with Biodextris since the beginning of our collaboration, and we look forward to working with them to make these vaccines accessible to patients.&#8221;<\/p>\n<p><strong>About Aramis Biotechnologies<\/strong><\/p>\n<p>Based in Quebec City, Aramis Biotechnologies is a Canadian company founded in 2023 that specializes in the production of innovative plant-based vaccines. As a company majority-owned by our employee-shareholders, our ambition is to develop innovative and sustainable solutions to current and future public health challenges. The Aramis team is grateful for the support provided by Innovation, Science and Economic Development Canada and the City of Quebec.<\/p>\n<p><strong>About Biodextris Inc.<\/strong><\/p>\n<p>Biodextris is a GMP-compliant complex biologics CDMO with over 20 years of experience in the development, GMP manufacturing, and bioanalysis of high-value, complex biologics. With clients ranging from the world&#8217;s largest biopharmaceutical companies to university spin-offs, Biodextris is the partner of choice for innovative biotech companies with new or complex processes looking to accelerate their path to clinical and commercialization. Biodextris&#8217; new center of excellence in Laval, which supports customers in manufacturing and analysis from preclinical development to commercialization, was developed with the support of the governments of Quebec and Canada, as well as Investissement Qu\u00e9bec.<\/p>\n\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t<li class=\"block-drawers__item js-a11y-drawer\">\n\t\t\t\t\t\t\t<h3 class=\"block-drawers__heading\" data-a11y-toggle>\n\t\t\t\t\t\t\t\t<button type=\"button\" class=\"block-drawers__trigger\" aria-expanded=\"false\" aria-controls=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-9\">\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__question\">December 5, 2024 &#8211; Government of Canada announces investment in Qu\u00e9bec-based Aramis Biotechnologies<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__icon\">\n\t\t\t\t\t\t\t\t\t\t<svg width=\"16\" height=\"10\" aria-hidden=\"true\" focusable=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t<use xlink:href=\"#ico-chevron-down\"\/>\n\t\t\t\t\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/button>\n\t\t\t\t\t\t\t<\/h3>\n\n\t\t\t\t\t\t\t<div class=\"wysiwyg block-drawers__panel\" id=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-9\" data-a11y-target hidden>\n\t\t\t\t\t\t\t\t<div class=\"mrgn-bttm-md\">\n<div class=\"row\">\n<div class=\"col-md-auto\">\n<div class=\"cmp-text\">\n<div class=\"mrgn-bttm-md\">\n<div class=\"row\">\n<div class=\"col-md-auto\">\n<div class=\"cmp-text\">\n<p><strong>Its project will maintain, advance and expand world-leading Canadian science focused on plant-based vaccine production<\/strong><\/p>\n<p><strong>December 5, 2024<\/strong> \u2013 Qu\u00e9bec, Quebec<\/p>\n<p>The Government of Canada is investing in a robust, dynamic and resilient life sciences ecosystem capable of responding to current and future health emergencies. Since March 2020, over $2.2\u00a0billion has been invested to strengthen domestic biomanufacturing capabilities and help keep Canadians healthy and safe.<\/p>\n<p>Today, the Honourable Jean-Yves Duclos, Minister of Public Services and Procurement and Quebec Lieutenant, on behalf of the Honourable Fran\u00e7ois-Philippe Champagne, Minister of Innovation, Science and Industry, announced a federal contribution of $40\u00a0million through the Strategic Innovation Fund (SIF) to support Aramis Biotechnologies\u2019 $80\u00a0million project to advance plant-based vaccines and therapeutics and to proceed with the development of a next-generation influenza vaccine.<\/p>\n<p>Aramis Biotechnologies, which is headquartered in Qu\u00e9bec, is seeking to advance plant-based vaccines and therapeutics against influenza and other diseases, leveraging and improving upon Medicago\u2019s world-leading technology platform. Medicago, a former Qu\u00e9bec-based biopharmaceutical company specializing in plant-based vaccine production, was the first and only Canadian-based company to develop and receive Health Canada authorization for a COVID-19 vaccine. Medicago ceased operations in February\u00a02023 after its parent company, Mitsubishi Chemical Group, initiated an orderly wind-down of the company.<\/p>\n<p>In December 2023, Aramis secured Medicago\u2019s key assets, including its technology platform, intellectual property and fully equipped pilot biomanufacturing facility, with the goal of further developing plant-based vaccine production in Canada. This SIF investment will support Aramis\u2019s process optimization and research and development activities so the company can continue to retain, improve and expand on this made-in-Canada science and technology platform. This investment will also support this new, fully Canadian-owned company in creating and maintaining at least 80\u00a0well-paying jobs.<\/p>\n<p>The investment in Aramis marks another significant step forward in the implementation of Canada\u2019s Biomanufacturing and Life Sciences Strategy. This project signifies an important opportunity to retain and continue to improve upon a leading made-in-Canada vaccine platform, strengthening the domestic vaccine technologies pipeline and building complementary capabilities that will ensure that Canada is well prepared to face future health emergencies.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div>\n<h2>Quotes<\/h2>\n<\/div>\n<blockquote data-emptytext=\"Blockquote\"><p>\u201cI am pleased to announce that today\u2019s investment in Aramis Biotechnologies will see our commitment come to fruition, with Aramis as the new pioneer of a world-leading vaccine technology platform that has the potential to contribute to Canada\u2019s pandemic preparedness and health security goals, complementing other investments made to secure the health and well-being of Canadians now and into the future.\u201d<br \/>\n\u2013 The Honourable Fran\u00e7ois-Philippe Champagne, Minister of Innovation, Science and Industry<\/p><\/blockquote>\n<blockquote data-emptytext=\"Blockquote\"><p>\u201cQuebec is emerging as a global innovation hub for the biomanufacturing and life sciences sector. Today\u2019s investment complements others we\u2019ve made to support this leading innovation ecosystem and to expand capabilities in vaccine technologies both in Quebec and across Canada. Our investment in Aramis Biotechnologies\u2019 project to advance this made-in-Canada innovation will increase our domestic ability to protect Canadians against future pandemics and other health emergencies. It will also help boost the entire life sciences ecosystem in Canada and add well-paying jobs for the Quebec City region at a cutting-edge employee-led company. The employees of Aramis believe strongly in this project, which is why they have invested $10 million of their own money, and our government is proud to partner with such passionate and committed owners.\u201d<br \/>\n\u2013 The Honourable Jean-Yves Duclos, Minister of Public Services and Procurement and Quebec Lieutenant<\/p><\/blockquote>\n<blockquote data-emptytext=\"Blockquote\"><p>\u201cWe are excited to initiate the first steps in further developing a next-generation plant-based platform. At Aramis, we aim to deliver a differentiated seasonal influenza vaccine to address a critical unmet need. Our employees are strongly committed to collective success, investing $10 million over three years. Additionally, we have secured $20\u00a0million from private Canadian investors to strategically maintain the know-how and the flexible capacity of this vaccine production technology in Canada. Our close partnership with the Government of Canada will also facilitate access to an advanced vaccine platform for pandemic response. By leveraging cutting-edge plant-based technology, we strive to enhance vaccine accessibility and efficacy, ensuring better preparedness and protection for all Canadians.\u201d<br \/>\n\u2013 Fr\u00e9d\u00e9ric Ors, CEO of Aramis Biotechnologies<\/p><\/blockquote>\n<div>\n<h2>Quick facts<\/h2>\n<\/div>\n<ul>\n<li>The federal government\u2019s $40\u00a0million contribution supports Aramis\u2019s research and development activities to optimize the plant-based platform and to proceed with the development of a next-generation influenza vaccine (up to Phase II clinical trials). It will enable Aramis to advance its goal of leveraging Medicago\u2019s research and enhancing pandemic preparedness capabilities in Canada.<\/li>\n<li>Canada\u2019s <a href=\"https:\/\/ised-isde.canada.ca\/site\/biomanufacturing\/en\/overview-canadas-biomanufacturing-and-life-sciences-strategy\">Biomanufacturing and Life Sciences Strategy<\/a> presents a long-term vision to protect Canadians against future pandemics and other health emergencies and to grow an innovative, competitive domestic life sciences sector.<\/li>\n<li>This investment in Aramis will advance the goals of the strategy by retaining and growing specialized skill sets for plant-based vaccine and therapeutics production, strengthening the domestic pipeline of vaccine technologies with an important domestic asset that can complement existing platforms and provide the variety of options needed in the event of a pandemic or health emergency.<\/li>\n<li>The <a href=\"https:\/\/www.ic.gc.ca\/eic\/site\/125.nsf\/eng\/home\">Strategic Innovation Fund<\/a> (SIF) provides major investments in innovative projects that will help grow Canada\u2019s economy for the well-being of all Canadians. SIF covers all sectors of the economy and is available to for-profit and not-for-profit organizations, with the goal of supporting the Canadian innovation network.<\/li>\n<\/ul>\n<section class=\"lnkbx well\">\n<h2 class=\"mrgn-tp-0\">Associated links<\/h2>\n<ul>\n<li><a title=\"Agreement reached on retaining Medicago\u2019s strategic research and development assets in Canada and recovering payment from Medicago\" href=\"https:\/\/www.canada.ca\/en\/innovation-science-economic-development\/news\/2023\/12\/agreement-reached-on-retaining-medicagos-strategic-research-and-development-assets-in-canada-and-recovering-payment-from-medicago.html\">Agreement reached on retaining Medicago\u2019s strategic research and development assets in Canada and recovering payment from Medicago<\/a><\/li>\n<li><a title=\"Biomanufacturing: Advancing health sciences industry in Canada\" href=\"http:\/\/www.ic.gc.ca\/eic\/site\/151.nsf\/eng\/home\">Biomanufacturing: Advancing health sciences industry in Canada<\/a><\/li>\n<li><a title=\"Strategic Innovation Fund\" href=\"https:\/\/www.ic.gc.ca\/eic\/site\/125.nsf\/eng\/home\">Strategic Innovation Fund<\/a><\/li>\n<li><a title=\"Aramis Biotechnologies\" href=\"https:\/\/aramisbiotechnologies.com\/en\/\">Aramis Biotechnologies<\/a><\/li>\n<\/ul>\n<\/section>\n<div>\n<h2>Contacts<\/h2>\n<\/div>\n<p>Audrey Milette<br \/>\nPress Secretary<br \/>\nOffice of the Minister of Innovation, Science and Industry<br \/>\n<a href=\"mailto:audrey.milette@ised-isde.gc.ca\">audrey.milette@ised-isde.gc.ca<\/a><\/p>\n<p>Media Relations<br \/>\nInnovation, Science and Economic Development Canada<br \/>\n<a href=\"mailto:media@ised-isde.gc.ca\">media@ised-isde.gc.ca<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t<li class=\"block-drawers__item js-a11y-drawer\">\n\t\t\t\t\t\t\t<h3 class=\"block-drawers__heading\" data-a11y-toggle>\n\t\t\t\t\t\t\t\t<button type=\"button\" class=\"block-drawers__trigger\" aria-expanded=\"false\" aria-controls=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-10\">\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__question\">December 4, 2024 &#8211; Aramis Biotechnologies announces $30 million in Series A financing<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__icon\">\n\t\t\t\t\t\t\t\t\t\t<svg width=\"16\" height=\"10\" aria-hidden=\"true\" focusable=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t<use xlink:href=\"#ico-chevron-down\"\/>\n\t\t\t\t\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/button>\n\t\t\t\t\t\t\t<\/h3>\n\n\t\t\t\t\t\t\t<div class=\"wysiwyg block-drawers__panel\" id=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-10\" data-a11y-target hidden>\n\t\t\t\t\t\t\t\t<p class=\"gt-block has-text-align-center has-custom-green-bench-color has-text-color has-link-color has-small-font-size wp-elements-2 wp-block-paragraph\"><em><strong>Employees and private investors jointly contribute $30 million<\/strong><\/em><\/p>\n<p class=\"gt-block has-text-align-center has-custom-green-bench-color has-text-color has-link-color has-small-font-size wp-elements-3 wp-block-paragraph\"><strong><em>First funding for phase 1\/2 clinical trials of a new seasonal flu vaccine<\/em><\/strong><\/p>\n<p class=\"gt-block has-text-align-center has-custom-green-bench-color has-text-color has-link-color has-small-font-size wp-elements-4 wp-block-paragraph\"><em><strong>Major technological advances achieved in less than a year of operation<\/strong><\/em><\/p>\n<p>&nbsp;<\/p>\n<p class=\"gt-block has-text-align-justify has-small-font-size wp-block-paragraph\"><strong>Quebec City, Wednesday December 4, 2024<\/strong> Aramis Biotechnologies Inc (\u201cAramis\u201d), a company specializing in the production of innovative vaccines in plants, is proud to announce its Series A financing. The 30 million Canadian dollars financing was led jointly by Aramis employees and a group of Quebec City-area entrepreneurs.<\/p>\n<p class=\"has-text-align-justify has-small-font-size wp-block-paragraph\">All Aramis employees are shareholders, collectively investing $10 million. A group of entrepreneurs from the Quebec City region is rounding out the financing by investing $20 million. Following the acquisition of Medicago&#8217;s main assets, employees and investors united behind a common vision: to take over and develop this flagship of Quebec and Canadian biotechnology and engineering, and make Aramis a world leader in its field.<\/p>\n<p class=\"has-text-align-justify has-small-font-size wp-block-paragraph\">\u201cIn record time since starting operations in February 2024, we have achieved several important milestones such as recruiting nearly 80 employees with unique expertise, relaunching research and production operations, and initiating the first preclinical studies. This initial financing will enable us to carry out Phase 1 and 2 clinical studies, and prepare us for Phase 3 studies and commercialization in Canada,\u201d commented Fr\u00e9d\u00e9ric Ors, Chief Executive Officer of Aramis. \u201cWe are also proud to have already achieved several major technological breakthroughs, and look forward to sharing our results.\u201d<\/p>\n<p class=\"has-text-align-justify has-small-font-size wp-block-paragraph\">\u201cI would like to thank our employees, our investors, the federal government and the City of Qu\u00e9bec. With their support, our ambition is to establish a production platform in next-generation plants and develop a more effective seasonal flu vaccine with the potential to improve protection for at-risk populations\u201d.<\/p>\n<div class=\"wp-block-spacer\" aria-hidden=\"true\"><\/div>\n<p class=\"gt-block has-custom-purple-porthos-color has-text-color has-link-color has-small-font-size wp-elements-5 wp-block-paragraph\"><strong>About Aramis Biotechnologies<\/strong><\/p>\n<p class=\"has-text-align-justify has-link-color has-small-font-size wp-elements-6 wp-block-paragraph\">Based in Quebec City, Aramis Biotechnologies is a Canadian company founded in 2023 that specializes in the production of innovative vaccines in plants. As a majority employee-owned company, our ambition is to develop innovative and sustainable solutions to current and future public health challenges.<\/p>\n<p>Contact: Nathalie Charland<br \/>\n<a href=\"mailto:ncharland@aramisbiotechnologies.com\">ncharland@aramisbiotechnologies.com<\/a><\/p>\n<figure class=\"wp-block-table has-x-small-font-size\">\n<table class=\"has-fixed-layout\" style=\"height: 32px;\" width=\"257\">\n<tbody>\n<tr>\n<td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t<li class=\"block-drawers__item js-a11y-drawer\">\n\t\t\t\t\t\t\t<h3 class=\"block-drawers__heading\" data-a11y-toggle>\n\t\t\t\t\t\t\t\t<button type=\"button\" class=\"block-drawers__trigger\" aria-expanded=\"false\" aria-controls=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-11\">\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__question\">November 26, 2024 &#8211; Aramis Biotechnologies to take part in the 18th edition of the Forum de l&#8217;Industrie de la Sant\u00e9 de Qu\u00e9bec and the International Conference \u201cSustainable Health, a Vector for Socio-Economic Progress\u201de edition of the Quebec Health Industry Forum and the International Conference \u201cSustainable health, vector of socio-economic progress\u201d<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__icon\">\n\t\t\t\t\t\t\t\t\t\t<svg width=\"16\" height=\"10\" aria-hidden=\"true\" focusable=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t<use xlink:href=\"#ico-chevron-down\"\/>\n\t\t\t\t\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/button>\n\t\t\t\t\t\t\t<\/h3>\n\n\t\t\t\t\t\t\t<div class=\"wysiwyg block-drawers__panel\" id=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-11\" data-a11y-target hidden>\n\t\t\t\t\t\t\t\t<p class=\"gt-block has-custom-green-bench-color has-text-color has-link-color has-medium-font-size wp-elements-2 wp-block-paragraph\"><em>Aramis Chairman and CEO, Mr. Fr\u00e9d\u00e9ric Ors, will make an important announcement at the Forum.<\/em><\/p>\n<p class=\"gt-block has-small-font-size wp-block-paragraph\"><strong>Quebec, Tuesday November 26, 2024<\/strong> \u2013 Aramis Biotechnologies Inc. (\u201cAramis Biotechnologies\u201d), a company specializing in the production of innovative vaccines produced in plants, is proud to announce the participation of its President and CEO, Mr. Fr\u00e9d\u00e9ric Ors, in the <a href=\"https:\/\/www.quebecinternational.ca\/fr\/fisq\">Quebec Health Industry Forum<\/a> (FISQ), which will be held on December 4 and 5, 2024 at the Quebec City Convention Center. During this prestigious event, Mr. Ors will present a conference entitled \u201cAramis Biotechnologies: Propelling Biotechnology Towards New Horizons\u201d, on Thursday, December 5 at 10:30 a.m. Mr. Ors will present the unique business model and share the advances and innovations developed by the company. Mr. Ors will also take the opportunity to make an important announcement for the company&#8217;s deployment.<\/p>\n<p class=\"has-small-font-size wp-block-paragraph\">This conference will be an opportunity to discover how the company is pushing the boundaries of science to offer cutting-edge health solutions. The Quebec Health Industry Forum brings together industry leaders and innovators each year, providing a platform for exchange and collaboration to shape the future of health. Mr. Ors&#8217; participation in this event underscores Aramis Biotechnologies&#8217; commitment to being at the forefront of innovation and actively contributing to the progress of the industry.<\/p>\n<p class=\"gt-block has-small-font-size wp-block-paragraph\">On the sidelines of FISQ 2024, Mr. Ors will also participate in a panel discussion as part of the conference \u201c\u00a0<a href=\"https:\/\/www.ulaval.ca\/calendrier-ulaval\/sante-durable\/la-sante-durable-vecteur-de-progres-socioeconomique-conference-internationale\">Sustainable health, a vector of socio-economic progress\u00a0<\/a>\u00bb on Tuesday, December 3 at 10:45 a.m. at Universit\u00e9 Laval. This panel will bring together experts from Europe and Quebec to discuss the theme \u201cDisease prevention: a business opportunity for the benefit of society.\u201d<\/p>\n<p class=\"has-small-font-size wp-block-paragraph\">This international conference aims to bring together stakeholders \u2013 government partners, municipal decision-makers, economic actors, citizens and researchers \u2013 around a common vision of the profound impact of sustainable health on communities.<\/p>\n<p class=\"gt-block wp-block-paragraph\"><strong>Useful information :<\/strong><\/p>\n<p class=\"gt-block has-small-font-size wp-block-paragraph\"><strong>Conference at <\/strong><a href=\"https:\/\/www.quebecinternational.ca\/fr\/fisq\"><strong>FISQ 2024<\/strong><\/a><strong>:<\/strong><\/p>\n<ul class=\"wp-block-list\">\n<li class=\"has-small-font-size\"><strong>Date:<\/strong>\u00a05th December 2024<\/li>\n<li class=\"has-small-font-size\"><strong>Location: <\/strong>\u00a0Quebec City Convention Center<\/li>\n<li class=\"has-small-font-size\"><strong>Conference:<\/strong>\u00a0\u201cAramis Biotechnologies: Propelling Biotechnology Towards New Horizons\u201d<\/li>\n<li class=\"has-small-font-size\"><strong>Hour :<\/strong>\u00a010:30<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">\n<p class=\"gt-block has-small-font-size wp-block-paragraph\"><strong>Panel at the <\/strong><a href=\"https:\/\/www.ulaval.ca\/calendrier-ulaval\/sante-durable\/la-sante-durable-vecteur-de-progres-socioeconomique-conference-internationale\"><strong>Sustainable Health Conference<\/strong><\/a><strong>:<\/strong><\/p>\n<ul class=\"wp-block-list\">\n<li class=\"has-small-font-size\"><strong>Date:<\/strong>\u00a03th December 2024<\/li>\n<li class=\"has-small-font-size\"><strong>Location: <\/strong>\u00a0The Circle, Alphonse-Desjardins Pavilion of Laval University and online<\/li>\n<li class=\"has-small-font-size\"><strong>Panel :<\/strong>\u00a0\u201cDisease prevention: a business opportunity for the benefit of society\u201d<\/li>\n<li class=\"has-small-font-size\"><strong>Hour :<\/strong>\u00a010:45<\/li>\n<\/ul>\n\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t<li class=\"block-drawers__item js-a11y-drawer\">\n\t\t\t\t\t\t\t<h3 class=\"block-drawers__heading\" data-a11y-toggle>\n\t\t\t\t\t\t\t\t<button type=\"button\" class=\"block-drawers__trigger\" aria-expanded=\"false\" aria-controls=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-12\">\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__question\">December 8, 2023 &#8211; Aramis Biotechnologies unveils its establishment and takes on the mission of harnessing the power of plants for the benefit of human health.<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"block-drawers__icon\">\n\t\t\t\t\t\t\t\t\t\t<svg width=\"16\" height=\"10\" aria-hidden=\"true\" focusable=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t<use xlink:href=\"#ico-chevron-down\"\/>\n\t\t\t\t\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/button>\n\t\t\t\t\t\t\t<\/h3>\n\n\t\t\t\t\t\t\t<div class=\"wysiwyg block-drawers__panel\" id=\"block_189f7e5e3bd5aeb04cf94aa1b202f5b0-panel-12\" data-a11y-target hidden>\n\t\t\t\t\t\t\t\t<p class=\"gt-block has-medium-font-size wp-block-paragraph\"><strong>Quebec, Friday December 8, 2023<\/strong> Aramis Biotechnologies Inc. (&#8220;Aramis Biotechnologies&#8221;), an innovative player in the biotechnology sector, proudly announces its official establishment and commitment to revolutionize the life sciences landscape. Armed with a passion for innovation and a dedication to improving public health, Aramis Biotechnologies is committed to making significant strides in the field of vaccine biomanufacturing and pandemic preparedness.<\/p>\n<p class=\"has-medium-font-size wp-block-paragraph\">Based in Quebec City, Canada, Aramis Biotechnologies leverages the unique capabilities of plant cells to develop a new generation of biomanufacturing platform within plants.<\/p>\n<p class=\"has-medium-font-size wp-block-paragraph\">The team at Aramis Biotechnologies boasts two decades of experience in the research and development of plant-produced vaccines, comprising an initial group of 14 experts determined to demonstrate the value of this biofabrication platform.<\/p>\n<p class=\"has-medium-font-size wp-block-paragraph\">By combining cutting-edge research, innovative and promising technology, and a team of experts, Aramis Biotechnologies is poised to successfully fulfill its mission of developing new biotechnological products for human health.<\/p>\n<p class=\"has-medium-font-size wp-block-paragraph\">&#8220;We are confident in the promising future of plant biofabrication technology, and we aim to collectively contribute to the protection of the Canadian population by offering innovative solutions to address public health challenges and confront future pandemics.<\/p>\n<p class=\"has-medium-font-size wp-block-paragraph\">We want to thank all our partners who have made this project possible, especially our collaborators and investors, the Governments of Canada and Quebec, the city of Quebec, and Quebec International&#8221; \u2013 Fr\u00e9d\u00e9ric Ors, President of Aramis Biotechnologies.<\/p>\n\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t\t<\/ul>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n<div class=\"item wysiwyg component-paragraph\"  ><div class=\"container\">\n<p class=\"wp-block-paragraph\"><\/p>\n<\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":1027,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-1194","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<title>News - Aramis Biotechnologies<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/aramisbiotechnologies.com\/en\/a-propos\/nouvelles\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News - Aramis Biotechnologies\" \/>\n<meta property=\"og:url\" content=\"https:\/\/aramisbiotechnologies.com\/en\/a-propos\/nouvelles\/\" \/>\n<meta property=\"og:site_name\" content=\"Aramis Biotechnologies\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/aramisbiotechnologies\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-13T20:04:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/aramisbiotechnologies.com\/wp-content\/uploads\/2026\/09\/poster.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/aramisbiotechnologies.com\\\/en\\\/a-propos\\\/nouvelles\\\/\",\"url\":\"https:\\\/\\\/aramisbiotechnologies.com\\\/en\\\/a-propos\\\/nouvelles\\\/\",\"name\":\"News - Aramis Biotechnologies\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/aramisbiotechnologies.com\\\/en\\\/#website\"},\"datePublished\":\"2026-09-03T13:32:25+00:00\",\"dateModified\":\"2026-10-13T20:04:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/aramisbiotechnologies.com\\\/en\\\/a-propos\\\/nouvelles\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/aramisbiotechnologies.com\\\/en\\\/a-propos\\\/nouvelles\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/aramisbiotechnologies.com\\\/en\\\/a-propos\\\/nouvelles\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/aramisbiotechnologies.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"About\",\"item\":\"https:\\\/\\\/aramisbiotechnologies.com\\\/en\\\/a-propos\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/aramisbiotechnologies.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/aramisbiotechnologies.com\\\/en\\\/\",\"name\":\"Aramis Biotechnologies\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/aramisbiotechnologies.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/aramisbiotechnologies.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Organization\",\"Corporation\"],\"@id\":\"https:\\\/\\\/aramisbiotechnologies.com\\\/en\\\/#organization\",\"name\":\"Aramis Biotechnologies\",\"url\":\"https:\\\/\\\/aramisbiotechnologies.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/aramisbiotechnologies.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/aramisbiotechnologies.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/logo-696x696-1.webp\",\"contentUrl\":\"https:\\\/\\\/aramisbiotechnologies.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/logo-696x696-1.webp\",\"width\":696,\"height\":696,\"caption\":\"Aramis Biotechnologies\"},\"image\":{\"@id\":\"https:\\\/\\\/aramisbiotechnologies.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/aramisbiotechnologies\\\/\",\"https:\\\/\\\/ca.linkedin.com\\\/company\\\/aramisbiotechnologies\"]}]}<\/script>","yoast_head_json":{"title":"News - Aramis Biotechnologies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/aramisbiotechnologies.com\/en\/a-propos\/nouvelles\/","og_locale":"en_US","og_type":"article","og_title":"News - Aramis Biotechnologies","og_url":"https:\/\/aramisbiotechnologies.com\/en\/a-propos\/nouvelles\/","og_site_name":"Aramis Biotechnologies","article_publisher":"https:\/\/www.facebook.com\/aramisbiotechnologies\/","article_modified_time":"2026-10-13T20:04:17+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/aramisbiotechnologies.com\/wp-content\/uploads\/2026\/09\/poster.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/aramisbiotechnologies.com\/en\/a-propos\/nouvelles\/","url":"https:\/\/aramisbiotechnologies.com\/en\/a-propos\/nouvelles\/","name":"News - Aramis Biotechnologies","isPartOf":{"@id":"https:\/\/aramisbiotechnologies.com\/en\/#website"},"datePublished":"2026-09-03T13:32:25+00:00","dateModified":"2026-10-13T20:04:17+00:00","breadcrumb":{"@id":"https:\/\/aramisbiotechnologies.com\/en\/a-propos\/nouvelles\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/aramisbiotechnologies.com\/en\/a-propos\/nouvelles\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/aramisbiotechnologies.com\/en\/a-propos\/nouvelles\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/aramisbiotechnologies.com\/en\/"},{"@type":"ListItem","position":2,"name":"About","item":"https:\/\/aramisbiotechnologies.com\/en\/a-propos\/"},{"@type":"ListItem","position":3,"name":"News"}]},{"@type":"WebSite","@id":"https:\/\/aramisbiotechnologies.com\/en\/#website","url":"https:\/\/aramisbiotechnologies.com\/en\/","name":"Aramis Biotechnologies","description":"","publisher":{"@id":"https:\/\/aramisbiotechnologies.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/aramisbiotechnologies.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Organization","Corporation"],"@id":"https:\/\/aramisbiotechnologies.com\/en\/#organization","name":"Aramis Biotechnologies","url":"https:\/\/aramisbiotechnologies.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/aramisbiotechnologies.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/aramisbiotechnologies.com\/wp-content\/uploads\/2026\/09\/logo-696x696-1.webp","contentUrl":"https:\/\/aramisbiotechnologies.com\/wp-content\/uploads\/2026\/09\/logo-696x696-1.webp","width":696,"height":696,"caption":"Aramis Biotechnologies"},"image":{"@id":"https:\/\/aramisbiotechnologies.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/aramisbiotechnologies\/","https:\/\/ca.linkedin.com\/company\/aramisbiotechnologies"]}]}},"_links":{"self":[{"href":"https:\/\/aramisbiotechnologies.com\/en\/wp-json\/wp\/v2\/pages\/1194","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aramisbiotechnologies.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/aramisbiotechnologies.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/aramisbiotechnologies.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/aramisbiotechnologies.com\/en\/wp-json\/wp\/v2\/comments?post=1194"}],"version-history":[{"count":6,"href":"https:\/\/aramisbiotechnologies.com\/en\/wp-json\/wp\/v2\/pages\/1194\/revisions"}],"predecessor-version":[{"id":1202,"href":"https:\/\/aramisbiotechnologies.com\/en\/wp-json\/wp\/v2\/pages\/1194\/revisions\/1202"}],"up":[{"embeddable":true,"href":"https:\/\/aramisbiotechnologies.com\/en\/wp-json\/wp\/v2\/pages\/1027"}],"wp:attachment":[{"href":"https:\/\/aramisbiotechnologies.com\/en\/wp-json\/wp\/v2\/media?parent=1194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}